A method for constructing a non-small cell lung cancer prognosis marker and a prognosis model and application thereof
By constructing a prognostic model for non-small cell lung cancer based on m6A-related genes, the problem of the inability to accurately assess the prognosis of non-small cell lung cancer in existing technologies has been solved, enabling precise assessment and early intervention of patient prognosis and improving patient outcomes.
Patent Information
- Application Number
- CN202111514088.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2021-12-10
- Publication Date
- 2026-08-18
- Estimated Expiration
- 2041-12-10
AI Technical Summary
The lack of accurate prognostic models for non-small cell lung cancer in current technologies makes it impossible to effectively assess patients' prognoses, affecting treatment choices and prognostic outcomes.
A prognostic model for non-small cell lung cancer based on m6A-related genes was constructed, including methylated genes, demethylated genes, and m6A-binding proteins. Significantly differentially expressed genes were screened using the TCGA database, and a risk score model was constructed. The prognostic risk of patients was assessed by combining the proportion of immune cells and the KEGG signaling pathway.
It provides an accurate and sensitive prognostic assessment tool that can predict the risk of poor prognosis in patients with non-small cell lung cancer at an early stage, helping doctors to take timely intervention measures and improve patient prognosis.